VHL and nonpapillary renal cell carcinoma: Inactivation of the von Hippel Lindau (VHL) gene is a hallmark of the majority of cases of sporadic ccRCC, and the change in its downstream HIF-VEGF signaling pathway results in the use of antiangiogenic targeted therapies, which are now first line in the treatment of advanced renal tumors.